Spotlight on Chronic Lymphocytic Leukemia: Exploring the Continued Evolution of Bruton Tyrosine Kinase Inhibitors for Our Patients

Did you know there are 3 Bruton tyrosine kinase (BTK) inhibitors approved to treat chronic lymphocytic leukemia (CLL) in Europe? Credit available for this activity expires: 1/4/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/986280?ecd=bdc_podcast_libsyn_mscpedu